Signatures of T and B Cell development, functional responses and PD-1 upregulation after HCMV latent infections and reactivations in Nod.Rag.Gamma mice humanized with cord blood CD34+ cells
Creators: name: Theobald, Sebastian Julian
name: Khailaie, Sahamoddin
name: Meyer-Hermann, Michael
name: Volk, Valery
name: Olbrich, Henning
name: Danisch, Simon
name: Gerasch, Laura
name: Schneider, Andreas
name: Sinzger, Christian
name: Schaudien, Dirk
name: Lienenklaus, Stefan
name: Riese, Peggy
name: Guzman, Carlos A.
name: Ferreira De Figueiredo, Constança Sofia
name: Von Kaisenberg, Constantin
name: Spineli, Loukia M.
name: Gläsener, Stephanie
name: Meyer-Bahlburg, Almut
name: Ganser, Arnold
name: Schmitt, Michael
name: Mach, Michael
name: Messerle, Martin
name: Stripecke, Renata
Publisher: name: Universität Ulm
Year: 2018
Subjects: subject: HCMV
subject: reactivation
subject: humanized mice
subject: T cell maturation
subject: B cell class switch
subject: optical imaging analyses
subject: principal component analyses
subject: linear discriminant analyses
subject: DDC 610 / Medicine &amp; health
subject: Cytomegalovirus
subject: B-Lymphocytes; Immunology
subject: T-Lymphocytes; Immunology
subject: Optical imaging
subject: Cytomegalie-Virus
subject: B-Lymphozyt
subject: T-Lymphozyt
subject: Immunreaktion

description: Human cytomegalovirus (HCMV) latency is typically harmless but reactivation can be largely detrimental to immune compromised hosts. We modeled latency and reactivation using a traceable HCMV laboratory strain expressing the Gaussia luciferase reporter gene (HCMV/GLuc) in order to interrogate the viral modulatory effects on the human adaptive immunity. Humanized mice with long-term (more than 17 weeks) steady human T and B cell immune reconstitutions were infected with HCMV/GLuc and 7 weeks later were further treated with granulocyte-colony stimulating factor (G-CSF) to induce viral reactivations. Whole body bio-luminescence imaging analyses clearly differentiated mice with latent viral infections vs. reactivations. Foci of vigorous viral reactivations were detectable in liver, lymph nodes and salivary glands. The number of viral genome copies in various tissues increased upon reactivations and were detectable in sorted human CD14+, CD169+, and CD34+ cells. Compared with non-infected controls, mice after infections and reactivations showed higher thymopoiesis, systemic expansion of Th, CTL, Treg, and Tfh cells and functional antiviral T cell responses. Latent infections promoted vast development of memory CD4+ T cells while reactivations triggered a shift toward effector T cells expressing PD-1. Further, reactivations prompted a marked development of B cells, maturation of IgG+ plasma cells, and HCMV-specific antibody responses. Multivariate statistical methods were employed using T and B cell immune phenotypic profiles obtained with cells from several tissues of individual mice. The data was used to identify combinations of markers that could predict an HCMV infection vs. reactivation status. In spleen, but not in lymph nodes, higher frequencies of effector CD4+ T cells expressing PD-1 were among the factors most suited to distinguish HCMV reactivations from infections. These results suggest a shift from a T cell dominated immune response during latent infections toward an exhausted T cell phenotype and active humoral immune response upon reactivations. In sum, this novel in vivo humanized model combined with advanced analyses highlights a dynamic system clearly specifying the immunological spatial signatures of HCMV latency and reactivations. These signatures can be merged as predictive biomarker clusters that can be applied in the clinical translation of new therapies for the control of HCMV reactivation.